AHA today urged the Health Resources and Services Administration to implement without further delay its final regulation on 340B drug ceiling prices and civil monetary penalties for manufacturers. “By failing to implement the final rule, drug manufacturers can continue to overcharge 340B hospitals by violating the ceiling price policy without repercussion,” AHA said. HRSA’s rulemaking on these issues began eight years ago, and since January 2017, the implementation date for the final regulation has been delayed five times. Earlier this month, HRSA proposed to delay the rule’s implementation date from July 1, 2018 to July 1, 2019. In addition, AHA expressed support for HRSA’s decision to codify its “penny pricing policy” to strengthen the agency’s oversight of 340B ceiling prices and to discourage manufacturers from raising prices faster than inflation. “We look forward to working with HRSA on further guidance on the 340B ceiling reporting system and how 340B hospitals and covered entities can access ceiling price information to establish instances of manufacturer overcharging,” AHA said.

Related News Articles

Insights and Analysis
In this guest column, Kenneth Kaufman, chair of Kaufman Hall, discusses how hospitals need scale to keep pace in today’s environment, as well as continue to…
Chairperson's File
We look ahead with optimism as we advance the goals of improving health care quality, equity, access and affordability for all Americans.  
The Federal Trade Commission’s approach to reviewing hospital mergers “is overbroad, does not properly credit the many pro-consumer benefits of hospital…
The AHA today voiced support for a Centers for Medicare…
The AHA’s Institute for Diversity and Health Equity today named Duane Elliott Reynolds as its new president and CEO.
A federal judge in Texas last night ruled that the entire Affordable Care is unconstitutional because Congress repealed the tax penalty enforcing the law's…